Clinical Trial Goal
To find out:
- The highest dose of ABBV-291 that's safe to give
- If ABBV-291 is safe and works well to treat NHL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have B-cell NHL that has relapsed or is refractory. Some examples include:
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Lymphoblastic lymphoma
- Mantle cell lymphoma (MCL)
- Marginal zone lymphoma (MZL)
- Waldenström macroglobulinemia
- Have been treated with a drug that targets CD79b. Your doctor can tell you this
- Have not been treated with an antibody drug conjugate containing topoisomerase I inhibitor. Your doctor can tell you this
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
ABBV-291 is an investigational drug that researchers believe will help treat NHL that has relapsed or is refractory.
You’ll get:
You’ll get:
- ABBV-291 – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 6 years.
The Food and Drug Administration (FDA) has not yet approved ABBV-291.
Locations
Sponsors
lead: AbbVie
